Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT XERIS BIOPHARMA HOLDINGS, INC.

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS)
Listen to this Section


$5.90
-0.1050 ( -1.75% ) 441.0K

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Market Data


Open $5.90
Previous Close $6.00
Volume 441.0K
Market Cap $1.04B
Day Range $5.58 - $7.04
52 Week Range $4.30 - $10.08
Shares Outstanding 172.64M
Change % -1.75%
Net Change ▼ -0.1050
Insider Ownership -0.02%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2018
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -4,631,992.00

Date Type Amount Purchased Purchaser
2025-06-16 Buy 25000.00 McCulloch Kevin
2024-08-13 Buy 4515.00 Schmid John P.
2024-08-12 Buy 4285.00 Schmid John P.
2024-08-09 Sale -3460.00 Pieper Steven
2024-08-09 Sale -14037.00 Hecht Beth
2024-08-09 Sale -7497.00 JOHNSON KENNETH ERLAND
2024-08-02 Sale -150000.00 McCulloch Kevin
2024-08-02 Sale -250000.00 Shannon John Patrick Jr
2024-06-05 Sale -50000.00 Kong Garheng
2024-06-05 Sale -50000.00 Schmid John P.

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jun 04, 2025
8-k 8K-related 73 Jun 03, 2025

Latest News


× Before browsing our site, please accept our cookies policy